Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole in Invasive Fungal Diseases (VITAL)
NCT00634049Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2008
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of isavuconazole in invasive aspergillosis (IA), mucormycosis and invasive fungal disease (IFD), sponsored by Astellas Pharma. Primary endpoint: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC). Started Apr 2008; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)mucormycosisinvasive fungal disease (IFD)
Beyond the preview
Go deeper on NCT00634049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634049.